AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of treating anxiety comprising ~~the step of~~ introducing into the central nervous system of a subject in need thereof a therapeutically effective amount of an inhibitor of dipeptidyl peptidase IV (DP IV) enzyme whereby enzymatic activity of said enzyme is reduced.

2. (Currently Amended) A method for reducing degradation of ~~the~~ endogenous CNS-localized neuropeptide Y (NPY) for ~~the~~ treatment of anxiety, the method comprising ~~the step of~~ introducing into the central nervous system of a subject in need thereof a therapeutically effective amount of a competitive inhibitor of dipeptidyl peptidase (DP IV).

3. (Previously Presented) The method of claim 1 wherein said inhibitor is selected from the group consisting of N-(N'-substituted glycyl)-2-cyanopyrrolidines, L-*threo*-isoleucyl thiazolidine, L-*threo*-isoleucyl pyrrolidine, L-*allo*-isoleucyl thiazolidine and L-*allo*-isoleucyl pyrrolidine.

4. (Previously Presented) The method of claim 1 wherein said inhibitor is present in a physiologically compatible drug delivery vehicle.

5. (Currently Amended) A ~~The~~ method ~~of claim 1 wherein said inhibitor is~~ of treating anxiety comprising introducing into the central nervous system a therapeutically effective amount of an inhibitor of dipeptidyl peptidase IV enzyme formulated in combination with NPY.

6. (Previously Presented) The method of claim 1 wherein introducing of said inhibitor of dipeptidyl peptidase IV is parenteral.

7. (Previously Presented) The method of claim 2 wherein said inhibitor is present in a physiologically compatible drug delivery vehicle.

8. (Cancelled)

9. (Previously Presented) The method of claim 3 wherein said inhibitor is formulated as prodrug of the free inhibitors.

10. (Previously Presented) The method of claim 2 wherein said introducing of said DP IV-inhibitor is parenteral.

11. (Previously Presented) The method of claim 3 wherein said introducing of said DP IV-inhibitor is parenteral.

12. (Previously Presented) The method of claim 4 wherein said introducing of said DP IV-inhibitor is parenteral.

13. (Currently Amended) The method of claim 5 wherein said introducing of said DP IV-inhibitor in combination with NPY is ~~applied~~ parenteral.

14. (Previously Presented) The method of claim 2, wherein said DP IV-inhibitor is selected from the group consisting of N-(N'-substituted glycyl)-2-cyanopyrrolidines, L-*threo*-isoleucyl thiazolidine, L-*threo*-isoleucyl pyrrolidine, L-*allo*-isoleucyl thiazolidine and L-*allo*-isoleucyl pyrrolidine.

15. (Previously Presented) The method of claim 5, wherein said DP IV-inhibitor is selected from the group consisting of N-(N'-substituted glycyl)-2-cyanopyrrolidines, L-*threo*-isoleucyl thiazolidine, L-*threo*-isoleucyl pyrrolidine, L-*allo*-isoleucyl thiazolidine and L-*allo*-isoleucyl pyrrolidine